RHUMBLINE ADVISERS - KINNATE BIOPHARMA INC ownership

KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 86 filers reported holding KINNATE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 1.3%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of KINNATE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$4,106
-70.5%
2,933
-36.2%
0.00%
Q2 2023$13,938
+4162.4%
4,600
-91.2%
0.00%
Q1 2023$327
+16.4%
52,373
+13.7%
0.00%
Q4 2022$281
-99.9%
46,045
+0.6%
0.00%
-100.0%
Q3 2022$547,000
+0.9%
45,773
+6.6%
0.00%0.0%
Q2 2022$542,000
+50.1%
42,957
+33.9%
0.00%
Q1 2022$361,000
-32.6%
32,079
+6.0%
0.00%
-100.0%
Q4 2021$536,000
-22.3%
30,270
+1.0%
0.00%0.0%
Q3 2021$690,000
+91.7%
29,972
+93.9%
0.00%
Q2 2021$360,000
-1.1%
15,455
+32.1%
0.00%
Q1 2021$364,00011,6970.00%
Other shareholders
KINNATE BIOPHARMA INC shareholders Q3 2022
NameSharesValueWeighting ↓
Foresite Capital Management IV, LLC 9,671,643$60,447,76931.36%
Vida Ventures Advisors, LLC 2,207,772$13,798,57518.88%
Lynx1 Capital Management LP 2,214,250$13,839,06311.54%
Foresite Capital Management V, LLC 1,975,001$12,343,7569.12%
Nextech Invest Ltd. 2,329,480$14,559,2506.08%
Ally Bridge Group (NY) LLC 109,393$683,7060.90%
Orbimed Advisors 5,143,629$32,147,6810.63%
RA Capital Management 4,264,144$26,650,9000.60%
Novo Holdings A/S 815,707$5,098,1690.34%
HARVARD MANAGEMENT CO INC 498,001$3,112,5060.33%
View complete list of KINNATE BIOPHARMA INC shareholders